Clinical Trial Update: A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type [Phase 2]

View source ↗

Summary

Phase 2 dose titration study of CPC-201 in dementia of Alzheimer's type has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia of Alzheimer Type

Drugs mentioned

• CPC-201

Snippet

Sponsor: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc | Conditions: Dementia of Alzheimer's Type | Phase 2 | Status: COMPLETED | Results posted: 2019-03-05